UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 3,956	$ 4,214
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation	156	155
Amortization	513	1,596
Provision for losses on/(recovery of) accounts receivable	(8)	1
Operating Lease, Right-of-Use Asset, Amortization Expense	14	13
Deferred income taxes	(192)	(3)
Stock-based compensation expense	79	50
Tax benefit attributable to exercise of stock options	9	2
Changes in operating assets and liabilities
Accounts receivable and other receivables	(214)	1,789
Inventories	271	(1,084)
Prepaid expenses and other current assets	(87)	25
Accounts payable	230	(193)
Accrued expenses	549	350
Total adjustments	1,320	2,701
Net cash provided by operating activities	5,276	6,915
CASH FLOWS FROM INVESTING ACTIVITIES
Property and equipment	(22)	(43)
Proceeds from sale of equipment	27	0
Net cash provided by/(used in) investing activities	5	(43)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock - options	96	21
Common stock purchased and retired	(2,990)	0
Payment of dividends	(1,089)	(1,070)
Net cash used in financing activities	(3,983)	(1,049)
Effect of exchange rate changes on cash	(358)	37
Net increase in cash and cash equivalents	940	5,860
Cash at beginning of period	92,868	75,052
Cash at end of period	93,808	80,912
Cash paid during the period for income taxes	105	129
Cash paid during the period for interest	$ 0	$ 0